Consequently, they identified SMAD3 and SMAD4 as potential biomarkers to predict the effectiveness of RT in pancreatic cancer.[25] These genetic variations and potential biomarkers should be the subject of further research, to gain a better understanding of inter- and intratumoral heterogeneity in pancreatic cancer. The gene discussed is SMAD4; the disease is familial pancreatic carcinoma.